Tenaris provides information pursuant to Luxembourg Transparency Law
By GlobeNewswire Published on June 19, 2025, 03:23 IST
LUXEMBOURG, June 18, 2025 (GLOBE NEWSWIRE) — Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) ('Tenaris', or the 'Company') announced today that the Company's controlling shareholder, San Faustin S.A. ('San Faustin'), has notified the Company that, as a result of Tenaris's open market repurchases of own shares under its share buyback program publicly announced on May 27, 2025, San Faustin has passively crossed a voting rights threshold triggering a notice requirement under the Luxembourg Transparency Law.
On the date hereof, San Faustin informed the Company that, following repurchases of shares by Tenaris in the period from June 9 to June 13, 2025 (disclosed by Tenaris on June 13, 2025, in accordance with the EU Market Abuse Regulation), the 713,605,187 shares of the Company that San Faustin owns represent 66.82% of the Company's voting rights. As required by the Luxembourg Transparency Law, San Faustin has further provided information on its control chain, wich confirms that the Company's control structure disclosed on the Company's 2024 annual report remains unchanged.
Tenaris is a leading global supplier of steel tubes and related services for the world's energy industry and certain other industrial applications.
Giovanni SardagnaTenaris1-888-300-5432
www.tenaris.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Questerre reports on AGM voting results
CALGARY, Alberta, June 18, 2025 (GLOBE NEWSWIRE) -- Questerre Energy Corporation ('Questerre' or the 'Company') (TSX,OSE:QEC) announced today that, at its annual meeting of shareholders held on June 18, 2025 (the 'Meeting'), all matters presented for approval at the Meeting were approved. At the Meeting, a vote was held by ballot which approved an ordinary resolution to fix the number of directors to be elected at the Meeting at six. In addition, each of the five nominees proposed in the Company's Management Information Circular dated May 8, 2025 (the 'Circular') were elected as directors to hold office until the next annual meeting of shareholders or until their successors are duly elected or appointed, unless their office is earlier vacated in accordance with the by-laws of the Company. The detailed results of the vote conducted by ballot are set out below: Nominees Votes For Votes Withheld Michael Binnion 52,542,484 (99.95%) 28,375 (0.05%) Mireille Fontaine 52,534,719 (99.93%) 36,140 (0.07%) Hans Jacob Holden 52,526,484 (99.92%) 44,375 (0.08%) Dennis Sykora 52,537,484 (99.94%) 33,375 (0.06%) Jauvonne Kitto 52,541,719 (99.94%) 29,140 (0.06%) Bjorn Inge Tonnessen 52,537,484 (99.94%) 33,375 (0.06%) By vote held by ballot, the ordinary resolution to approve the appointment of Ernst & Young LLP, Chartered Professional Accountants, as the auditors of the Company to hold office until the next annual meeting of shareholders or until their successors are appointed and authorizing the directors of the Company to fix their remuneration, was approved. By vote held by ballot, the ordinary resolution to adopt and approve the shareholder rights plan of the Corporation as set forth in the Circular, was approved. Questerre is an energy technology and innovation company. It is leveraging its expertise gained through early exposure to low permeability reservoirs to acquire significant high-quality resources. We believe we can successfully transition our energy portfolio. With new clean technologies and innovation to responsibly produce and use energy, we can sustain both human progress and our natural environment. Questerre is a believer that the future success of the oil and gas industry depends on a balance of economics, environment, and society. We are committed to being transparent and are respectful that the public must be part of making the important choices for our energy future. CONTACT: For further information, please contact: Questerre Energy Corporation Jason D'Silva, Chief Financial Officer (403) 777-1185 | (403) 777-1578 (FAX) |Email: info@ in to access your portfolio
Business Upturn
5 hours ago
- Business Upturn
Kane Biotech Provides Further Corporate Update
WINNIPEG, Manitoba, June 18, 2025 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (the 'Company', 'Kane' or 'Kane Biotech') provides updates on its reorganizational phase. The Company has terminated its exclusive distribution agreement with ProgenaCare Global LLC ('ProgenaCare') dated April 18, 2023 due to various material breaches by ProgenaCare of the agreement. Activities to resecure distribution for its products in the United States are underway. The Company recently received a notice of default from Prairies Economic Development Canada ('PrairiesCan'). The notice relates to the Contribution Agreement between Western Economic Diversification Canada (now PrairiesCan) and Kane Biotech dated August 6, 2019, in which PrairiesCan provided the Company with repayable contributions of $2,491,266. The contributions are repayable in 59 consecutive monthly installments of $42,000 and one final instalment of $13,266 on an unsecured, interest-free basis which commenced on April 1, 2023. Kane has made all required repayments from April 1, 2023 to date excepting that of the payment due June 1, 2025. The Company has been in communication with PrairiesCan prior to the notice whereby it requested a restructuring of the timing of the remaining loan repayments with the intention of repaying the outstanding balance in full. Kane previously advised on April 28, 2025, that an unsecured demand loan of $1 million (the 'Loan') from an insider of the Company was entered into and funds received. The lender has agreed to convert the Loan to a five-year, unsecured convertible debenture in the principal amount of $1 million (the 'Debenture') all of which is subject to the approval of the TSX Venture Exchange. Interest on the Debenture shall accrue at the rate of three percent (3%) per annum, compounded annually and payable at maturity. The Debenture is convertible into common shares of Kane at the option of the holder at a price of $0.10 per common share. There are no broker fees or commissions related to this matter. The conversion of the Loan to the Debenture is a 'related party transaction' as defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ('MI 61-101'). The Company is exempt from the formal valuation and minority approval requirements for related party transactions pursuant to Subsection 5.5(b) and Subsection 5.7(1)(e) of MI 61-101, respectively. The Company is now executing its clinical plan to underpin the commercial introduction of its revyveTM Antimicrobial Wound Gel and revyveTM Antimicrobial Wound Gel Spray in the US market. We are presently conducting clinical case series there with respected medical professionals in both chronic wound care and burn care patients which will result in the presentation of preclinical and clinical case series data in late 2025 and 2026. This press release does not constitute an offer to sell or the solicitation of an offer to buy this security, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. The securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom. About Kane Biotech Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results in serious clinical outcomes and significant cost. revyve™ addresses both biofilms and wound bacteria. For more information: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Caution Regarding Forward-Looking Information This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company's: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at The Company cautions that the foregoing list of factors that may affect future results is not exhaustive. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
5 hours ago
- Business Upturn
Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering
New Taipei City, Taiwan, June 18, 2025 (GLOBE NEWSWIRE) — Jyong Biotech Ltd. (Nasdaq: MENS) (the 'Company'), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced the closing of its initial public offering (the 'Offering') of 2,666,667 ordinary shares (the 'Ordinary Shares') at a public offering price of $7.5 per share for aggregate gross proceeds of approximately $20 million, before deducting underwriting discounts and other offering expenses. The Ordinary Shares commenced trading on Nasdaq Global Market on June 17, 2025, under the ticker symbol 'MENS'. The Offering closed on June 18, 2025. The Company has granted the underwriters an option, exercisable within 45 days from the date of the final prospectus, to purchase up to an additional 400,000 Ordinary Shares at the public offering price, less underwriting discounts, to cover over-allotments, if any. The Company intends to use the net proceeds from the Offering for (i) funding the additional Phase III trials of MCS-2 (API-2) and the new drug application of MCS-2 (40%); (ii) funding earlier phase trials if the Company is unable to demonstrate comparability (25%); (iii) funding the Phase II trial of PCP (10%); (iv) funding the Phase I clinical trial of IC (5%), and (v) general corporate purposes (20%). The Offering was conducted on a firm commitment basis. Joseph Stone Capital, LLC acted as sole underwriter for the Offering (the 'Underwriter'). Sichenzia Ross Ference Carmel LLP acted as U.S. securities counsel to the Company, and VCL Law LLP acted as U.S. securities counsel to the Underwriter, in connection with the Offering. A registration statement on Form F-1 (File No. 333-277725) relating to the Offering, as amended, was previously filed with the U.S. Securities and Exchange Commission (the 'SEC') and was declared effective by the SEC on June 16, 2025. The Offering was made only by means of a prospectus. Copies of the prospectus related to the Offering may be obtained from Joseph Stone Capital, LLC by standard mail to Joseph Stone Capital, LLC, 585 Stewart Ave., Suite L60-C, Garden City, NY 11530, or via email at [email protected] or by telephone at +1 (888) 302-5548. In addition, a copy of the final prospectus relating to the Offering, dated June 16, 2025, can also be obtained via the SEC's website at Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Jyong Biotech Ltd. Headquartered in Taiwan, Jyong Biotech a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, MCS-2, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers' health needs and seeks to be a valuable business organization that is held in high esteem by the public. For more information, please visit: Forward-Looking Statement This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as 'may, 'will, 'intend,' 'should,' 'believe,' 'expect,' 'anticipate,' 'project,' 'estimate' or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, the Company's statements regarding the intended use of the proceeds from the Offering. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the 'Risk Factors' section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. For more information, please contact: UnderwriterJoseph Stone Capital, LLC (888) 302-5548 [email protected]
